Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Watershed Informatics Exhibit at RESI JPM San Francisco

15 Dec
Madeline-Kelly
Madeline Kelly
Interview with Madeline Kelly, Head of Sales, Watershed Informatics

By Caitlin Dolegowski, Marketing Manager, LSN

Caiti
Caitlin Dolegowski

Watershed Informatics’ intuitive Data Lab platform empowers our clients to design, execute, and iterate their own sequencing analyses, shortening time between iterations and enabling more efficient and effective experimentation. They expedite and multiply the development of targeted, breakthrough therapies and diagnostics. Watershed returns to RESI this January as an exhibitor. In the following interview, Watershed’s Head of Sales, Madeline Kelly, provides insight on how Watershed came to be, their technology, team, and target customer.

Caiti Dolegowski (CD): Please introduce us to Watershed. Tell us about your technology and platform.

Madeline Kelly (MK): Watershed Informatics is the first fully verticalized bio-IT platform. Our Cloud Data Lab enables life sciences organizations of any size to perform mission-critical bioinformatics analyses (such as bulk, single-cell, and spatial transcriptomics; WGS, proteomics, protein folding, AI/ML etc.) at an order of magnitude less cost and complexity than existing solutions. With purpose-built infrastructure specifically optimized for catalyzing the life sciences development pipeline, our product enables biologists to analyze their own data and bioinformaticians to rapidly prototype and deploy bespoke analytic workflows across an organization.

CD: Tell us about Watershed’s team?

MK: We are a team of expert bioinformaticians, software engineers, and biologists inspired by one mission: to enable all scientists – regardless of their programming capabilities – to leverage multi-modal data for building better drugs faster.

CD: Watershed’s Cloud Data lab can be traced to a conversation between co-founders, Jonathan Wang and Mark Kalinich. What was the conversation and how do they complement each other?

MK: Jonathan and Mark have been friends since their first day of MIT – they were actually next-door neighbors freshman year! As a software engineer, Jonathan has always been fascinated by high-performance computational infrastructure. He co-founded an algorithmic trading firm while still a student at MIT. While there, he perfected the tech stack required to democratize access to petabyte-scale ML infrastructure for software engineers and financial researchers alike. Mark is a Harvard-trained physician-scientist with nearly 15 years of translational research experience across diagnostics and therapeutics development. His mission is to improve the lives of patients by developing and deploying the enabling technologies required to bring therapeutics out of the laboratory and into the clinic. Their expertise and passions directly intersect at the problem Watershed solves: uncorking the bottleneck for biotech and pharma’s data-intensive research efforts.

CD: Who is your target customer? And what are the different offerings you provide your clients?

MK: Our target customers want to successfully and efficiently analyze their big biology data (most often -omics, but also protein folding and high content imaging) without the massive overhead currently required. (To learn more about what we mean by overhead, download our white paper). With our no-code / low-code / high-code interoperability, our platform is useful to biologists and bioinformaticians alike.

CD: Do you have a process for assessing your clients’ needs? How does that work?

MK: Watershed employs a highly consultative sales and onboarding process. We thoroughly assess the needs of our customers by learning about their workflow, analysis, and visualization needs. Our team of bioinformaticians are ready to assist our clients from day 1.

CD: Could you give us examples of current Watershed clients and how they’ve utilized your informatics?

MK: Some of our clients include SalioGen, Cellino, SynDevRx, Rejuvenate Bio, Rarebase, Revitope, and a few stealth biotech startups. Our customers’ most common request is processing next-generation sequencing data across a variety of workflows (bulk, single-cell, and spatial RNAseq; whole genome and whole exome sequencing, bulk and single-cell ATACseq, immune repertoire sequencing, CRISPR-based analyses, custom sequencing libraries, etc) and technologies (Illumina, ONT, PacBio). In addition to other data-intensive workflows (metabolomics, proteomics, high-content imaging, protein-folding) and publicly available datasets (TCGA, CCLE, GTex, UKBB), our platform has been purpose-built to overlay advanced AI/ML techniques on these data, including deep learning, generative AI, structure-based learning models, and NLP, among others.

CD: We’re thrilled to Watershed back as an exhibitor at RESI JPM San Francisco! What would you like our RESI attendees to know about Watershed

MK: We are excited to join RESI JPM San Francisco as first-time attendees! We want to meet as many of you as possible, so swing by our booth to check out our platform and enter for a chance to win 1 free month of Watershed’s Cloud Data Lab (details available at the conference). See you there!

RESI-SF-2023-Banner-1100-wide

RESI JPM San Francisco 2023 Investor Panelists

15 Dec

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

RESI JPM San Francisco 2023 is fast approaching. The Life Science Nation (LSN) team has been busy putting together a program of 8 panels that provides latest insights on early-stage life science and healthcare.

We are excited to have invited a diverse lineup of panelists from different types of investment groups, including Big Pharma, corporate VCs, medtech strategics, traditional VCs, angels and family offices, to share their strategies and approaches on early-stage investment, perspectives on industry landscape, startup ecosystem and more. As a global conference, we are also delighted to have many international investors and cross-border investment groups to join and contribute to these dynamic discussions. The goal of RESI panels is to facilitate constructive conversations between investors and fundraising CEOs, and provide tactical advice on how companies can raise capital and acquire partnerships effectively. These must-see panels are great opportunities for founders and CEOs to engage with investors and kick off their fundraising journey of 2023.

Join the panelists below at RESI JPM San Francisco:


Mel Barsky
Director of Business Development
Centre for Aging + Brain Health Innovation (CABHI)

Lana Caron
Innovation Lead
Philips Ventures
Bruce Cohen
Bruce Cohen
Venture Partner
Xeraya Capital
Matt Deschner
Matt Deschner
Business Development & Licensing – Surgical Innovations
Medtronic

Gini Deshpande
Partner of Cathay Capital
Niels Emmerich
Niels Emmerich
Vice President, Global Head Search and Evaluation
AbbVie
Xi Fang
Xi Fang
Managing Partner
Button Capital
Jon Friedland
Jon Friedland
Managing Director, Ventures
Cleveland Clinic Ventures
Amit Garg
Amit Garg
Managing Partner
Tau Ventures
Lana Ghanem
Lana Ghanem
Managing Director
Hikma Ventures
Tom Gibbs
Tom Gibbs
Director
Debiopharm Innovation Fund
Gita Gupta
Gita Gupta
Partner
NextStep Ventures
Duncan Huston-Paterson
Duncan Huston-Paterson
Senior Manager, Business Development
Amgen
Kristin King
Kristin King
Member
Boston Harbor Angels
Fiona Mack
Fiona Mack
VP, Head of CoLaborator
Bayer
Nola Masterson
Nola Masterson
Managing Director
Science Futures
Andrew Meadow
Andrew Meadow
General Partner
Health Innovation Capital
Tamir Meiri
Tamir Meiri
Senior Manager, Venture Investments
Johnson & Johnson Innovation
Ole Mensching
Ole Mensching
Co-Founder and General Partner
Apollo Health Ventures
Ravi Mistry
Ravi Mistry
Angel Investor
John Parker
John Parker
Founder & Managing Director
Springhood Ventures
Armin Rump
Armin Rump
Manager, Global Business Development
Otsuka Pharmaceutical
Akhil Saklecha
Akhil Saklecha
Chief Scientific Officer, Acute Care
Danaher Corporation
Yoke Sin
Yoke Sin
Managing Partner
iGlobe Partners
Lesley Stolz
Lesley Stolz
Regional Vice President, Early Innovation Partnering
Johnson & Johnson Innovation
Sally Wang
Sally Wang
Venture Partner
Viva BioInnovator
Oscar Zhang
Oscar Zhang
Principal
Qiming Venture Partners
Lu Zhang
Lu Zhang
Managing Partner
Fusion Fund
Cheryl Zimberlin
Cheryl Zimberlin
Investment Director
M Ventures

RESI-SF-2023-Banner-1100-wide

Crafting the Perfect Message

15 Dec

By Karen Deyo, VP of Product, Israel BD, LSN

You’ve registered for a partnering conference.

You’ve filled out a profile in the partnering system detailing who you are and what your company does.

You’ve researched the investors in attendance and built a list of targets to book meetings with.

You hit “Request a Meeting” and freeze.

What message will increase your chances of the investor accepting the request?

Partnering is an involved process with multiple steps that must be taken to ensure optimal results. These steps often require major time investment, and we forget that, even after the hours we’ve poured into the process, none of it matters without a compelling message to pique the interest of a potential partner. Furthermore, this is a process that requires a plan for following up, since, as with any outreach, it will likely take more than one message to the investors to receive a response. These messages should be clear and concise, no more than a paragraph, highlighting your company and what makes it unique.

Life Science Nation (LSN) has developed and consolidated your partnering outreach into four separate messages:

  1. Introduction: The first message is the one where you introduce yourself and your company, as well as request a meeting. It’s ok if your target investor does not respond immediately (hence this system). To help them understand your position, it’s important to include the following:
  2. Company tagline (5-6 words explaining who you are and what you do)
  3. Elevator pitch (1-3 sentences describing the company and tech)
  4. Technology differentiation, product innovation, or market position
  5. Raise and milestone information
  6. Follow Up 1 (Product/Tech): Why is your product and technology unique? Is it first-in-class? Best-in-class? This is your opportunity to dive into your company’s differentiated value.
  7. Follow Up 2 (Management/Team): Highlight your management and team. How have your people had a notable impact on the business development? What makes your people special?
  8. Follow Up 3 (One Pager): Condense all the important messages you’ve already shared into a one-page tear sheet for quick and easy reference later.

It should go without saying that the perfect message is meaningless without a well-researched and formulated target list and marketing collateral at the ready. Think of the perfect message like how an athlete approaches the arena on game day. It’s the starting shot of a long and exciting process. It won’t replace the training and conditioning that got you to game day, but it’ll ensure you’re off with a competitive edge.

Check Out the IPC Finalists Who Will Be Pitching at RESI JPM San Francisco 2023!

8 Dec

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

With about a month left until RESI JPM San Francisco, LSN is very excited to announce the list of finalist companies who will be participating in the Innovator’s Pitch Challenge (IPC) at the upcoming RESI!

This round of IPC was the most popular one to date. With the increased interest, all the IPC slots were filled well before the initial application deadline.

Over 50 companies representing therapeutics, medical devices, diagnostics, digital health, and R&D / life science tools across the globe will be delivering a live pitch followed by a Q&A session with a panel of investors and industry experts. In addition, the companies will be presenting a poster showcasing their technology in the exhibit hall.

Below are the participating companies – if you will be attending RESI, please be on the lookout for them. If you are interested in seeing these pitches and engaging in one-on-one partnering with over 1,000 attendees expected to attend, you can register here!

RESI JPM San Francisco
Innovator’s Pitch Challenge Finalists

RESI-SF-2023-Banner-1100-wide

Global Tech Hub Gathering in San Francisco

8 Dec

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN
Tech hubs from around the world are coming to RESI in San Francisco! Tech hubs are a crucial part of the Life Science Nation (LSN) and RESI community as they provide capital, entrepreneurial support, lab space, and economic development for their cohort of aspiring scientist-entrepreneur and fundraising executives. With this immense support from tech hubs, their group of startups, who’ve raised less than $2M USD, can accelerate their entrepreneurship journey by participating in RESI at a discounted rate and taking advantage of LSN services. Ranging from universities, non-profits, incubators, accelerators, and regional and government organizations, they are all looking to connect with investors, strategic partners, and early-stage life science startups in San Francisco. Get to know these global communities of innovation!

Don’t see your organization on this list? Contact us to learn more about special offers for you and your startups!

RESI-SF-2023-Banner-1100-wide

International Delegations Gain Visibility and Recognition at RESI

8 Dec

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI JPM San Francisco will once again be a showcase for cutting edge technologies from distant regions of the globe. Because the RESI conference draws top life science investors and strategic partners, regional technology hubs see it as a chance to give their constituents direct access to funding opportunities and expansion into new markets.

Previous delegations from places including Korea, Quebec, Chile, Taiwan, Israel, Ontario and France have used RESI as a springboard for their companies. And this upcoming RESI JPM San Francisco 2023 will be no exception.

This RESI, the Israel Economic Mission to the West Coast, USA, and the Israel Export Institute are proud to showcase some of the companies making waves in the digital health field. They include companies with innovative technology focused on AI, Machine Learning, Voice Recognition, Big data, AR/ VR, Robotics, with disruptive solutions for Diagnostics Digital Imaging, Precision Medicine, Decision Support Systems, Clinical Workflow Management, Telemedicine, Remote Monitoring, and Smart Surgical Equipment, and many more.

Likewise, the Brisbane Economic Development Agency is sponsoring a cohort of hot MedTech and Digital Health companies from the Australian state of Queensland to come to San Francisco and showcase the technologies being developed in that part of the world that will have an impact everywhere. The members of the cohort have participated in a custom 2-month long educational program together with Life Science Nation that will culminate in San Francisco, where they will be well prepared to pitch and partner with global life science players.

Be sure to check out these technologies in the Innovator’s Pitch Challenge poster board section at RESI and say hello to their founders. They’ll be happy to tell you their stories.

RESI-SF-2023-Banner-1100-wide

Bridging the Gap between Academia and Industry

6 Dec

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Mansfield Bio-Incubator Chief Operating Officer, Alexander Margulis has been in the Life Sciences industry for over 20 years and is passionate about creating a robust and accessible entrepreneurial community among local universities, startups, and investors. Less than 1-hour away from Boston and Cambridge, the facility provides affordable private and shared spaces for research labs, mentorship and networking opportunities. In addition, they offer several resources such as access to professional advisors and assistance with government and private funding research applications. Currently, Mansfield Bio-Incubator hosts over 20 early-stage startups ranging from therapeutics, medical devices, and cleantech in the life sciences areas of oncology, women’s health, animal health, biomaterials, water purification, and more.

Listen to our conversation to learn more about how Alexander and his team are creating, growing, and ensuring the success of the next generation of life science companies at Mansfield Bio-Incubator.

Digital RESI March 2023 Email Banner.(NEWtouse)